Scalable, cost-efficient Go-To-Market with broad coverage distribution model

ir_statement / Sep 15, 2026 / receipt

Go-to-market efficiency through leading channel partners, with nationwide reach

ir_statement / Sep 15, 2026 / receipt

Scalable, cost-efficient Go-To-Market with broad coverage distribution model

ir_statement / Sep 15, 2026 / receipt

Go-to-market efficiency through leading channel partners, with nationwide reach

ir_statement / Sep 15, 2026 / receipt

During Q2, our commercial team added approximately 10 new distributed reps to the team they are working with. This opens the door to more territories and more potential customers. | Target these 10 ne

company_statement / Aug 17, 2026 / receipt, needs a key

In addition to actual sales, we're working on several substantial marketing collaborations, as well as clinical study initiatives that will call attention to the problem, as well as product solutions

company_statement / Aug 17, 2026 / receipt, needs a key

We've invested and will continue to invest in expanding our sales capacity as we expect opportunities generated through those investments to increasingly translate into revenue. | Target sales leaders

company_statement / Aug 17, 2026 / receipt, needs a key

We need to continue to both build and convert the product's commercial pipeline. We need to continue to innovate, creating new products that deliver better patient care and provide better value to our

company_statement / Aug 17, 2026 / receipt, needs a key